Institutional equity research analysts covering Greenwich LifeSciences maintain forward-looking price targets that vary widely due to the binary nature of clinical-stage biotechnology investing. While selective bullish targets stretch significantly higher based on potential commercialization milestones for the GP2 immunotherapy, these projections carry immense volatility and are heavily contingent upon successful trial readouts and regulatory clearances.